FCN-437c is under clinical development by Fochon Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FCN-437c’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FCN-437c is under development for the treatment of solid tumors including ER-positive and HER2-negative metastatic breast cancer, breast cancer and non-small cell lung cancer. The drug candidate is formulated as a capsule, tablet and administered through the oral route. It acts by targeting cyclin-dependent kinase (CDK) 4 and 6.
Fochon Pharmaceutical overview
Chongqing Fochon Pharmaceutical Co., Ltd. is engaged in the research and development of chemical drugs.
For a complete picture of FCN-437c’s drug-specific PTSR and LoA scores, buy the report here.